Abstract
The proteins Ure2, Sup35 and Rnq1 from the bakers yeast have infectious properties, termed prions, at the origin of heritable and transmissible phenotypic changes. It is widely believed that prion properties arise from the assembly of Ure2p, Sup35p and Rnq1p into insoluble fibrils. Yeast prions possess regions crucial for their propagation that can be either N- or C-terminal. These regions have unusual amino acid composition. They are very rich in glutamine and asparagine residues and resemble in that to huntingtin, a protein involved in the neurodegenerative Huntingtons disease. Yeast prions assembly process has been hypothesized to be the consequence of the properties of glutamines and asparagines to engage in polar protein-protein interactions, termed polar-zippers. While this can certainly occur under certain conditions, glutamine and asparagine residues can establish other kinds of interactions with a variety of amino acid residues thus mediating protein-protein interactions involved in the assembly of polypeptide chains into high molecular weight oligomers. This review details the interactions that can be established by glutamine and asparagine residues that may allow a better understanding of their role in mediating protein-protein interactions and prion propagation.
Keywords: Prion, [PSI+], [URE3], Sup35p, Ure2p, amyloid fibrils, native-like assemblies
Current Alzheimer Research
Title: Assembly of the Asparagine- and Glutamine-Rich Yeast Prions into Protein Fibrils
Volume: 5 Issue: 3
Author(s): Luc Bousset, Jimmy Savistchenko and Ronald Melki
Affiliation:
Keywords: Prion, [PSI+], [URE3], Sup35p, Ure2p, amyloid fibrils, native-like assemblies
Abstract: The proteins Ure2, Sup35 and Rnq1 from the bakers yeast have infectious properties, termed prions, at the origin of heritable and transmissible phenotypic changes. It is widely believed that prion properties arise from the assembly of Ure2p, Sup35p and Rnq1p into insoluble fibrils. Yeast prions possess regions crucial for their propagation that can be either N- or C-terminal. These regions have unusual amino acid composition. They are very rich in glutamine and asparagine residues and resemble in that to huntingtin, a protein involved in the neurodegenerative Huntingtons disease. Yeast prions assembly process has been hypothesized to be the consequence of the properties of glutamines and asparagines to engage in polar protein-protein interactions, termed polar-zippers. While this can certainly occur under certain conditions, glutamine and asparagine residues can establish other kinds of interactions with a variety of amino acid residues thus mediating protein-protein interactions involved in the assembly of polypeptide chains into high molecular weight oligomers. This review details the interactions that can be established by glutamine and asparagine residues that may allow a better understanding of their role in mediating protein-protein interactions and prion propagation.
Export Options
About this article
Cite this article as:
Bousset Luc, Savistchenko Jimmy and Melki Ronald, Assembly of the Asparagine- and Glutamine-Rich Yeast Prions into Protein Fibrils, Current Alzheimer Research 2008; 5 (3) . https://dx.doi.org/10.2174/156720508784533303
DOI https://dx.doi.org/10.2174/156720508784533303 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitric Oxide (NO) Signaling as a Potential Therapeutic Modality Against Psychostimulants
Current Pharmaceutical Design Fibrillar β-Amyloid Impairs the Late Phase of Long Term Potentiation
Current Alzheimer Research Miglustat: Substrate Reduction Therapy for Lysosomal Storage Disorders Associated with Primary Central Nervous System Involvement
Recent Patents on CNS Drug Discovery (Discontinued) Safety and Tolerability of Agomelatine: Focus on Hepatotoxicity
Current Drug Metabolism MicroRNAs in CAG Trinucleotide Repeat Expansion Disorders: an Integrated Review of the Literature
CNS & Neurological Disorders - Drug Targets Physical Means of Stratum Corneum Barrier Manipulation to Enhance Transdermal Drug Delivery
Current Drug Delivery Proceeding of the 8th Alcohol Hangover Research Group Meeting
Current Drug Abuse Reviews Preferential Formulation of Second Generation Antipsychotic Asenapine as Inclusion Complex with Sulphobutylether-βCD (Captisol): In vitro and In vivo Evaluation
Current Drug Delivery Update for Cancer Therapy with β-Lapachone
Medicinal Chemistry Reviews - Online (Discontinued) The Neuroprotective Role of PEDF: Implication for the Therapy of Neurological Disorders
Current Molecular Medicine Mechanism of Organophosphates (Nerve Gases and Pesticides) and Antidotes: Electron Transfer and Oxidative Stress
Current Medicinal Chemistry Analysis of Electrical Brain Waves in Neurotoxicology: Gamma- Hydroxybutyrate
Current Neuropharmacology Functional Connectivity Analysis of Brain Default Mode Networks Using Hamiltonian Path
CNS & Neurological Disorders - Drug Targets α-Melanocyte Stimulating Hormone as a Potential Therapy for Alzheimer's Disease
Current Alzheimer Research Acknowledgements to Reviewers:
Recent Patents on CNS Drug Discovery (Discontinued) The Hypothalamic-Pituitary-Adrenal Axis: What can it Tell us About Stressors?
CNS & Neurological Disorders - Drug Targets From Antioxidant Chelators to Site-Activated Multi-Target Chelators Targeting Hypoxia Inducing Factor, Beta-Amyloid, Acetylcholinesterase and Monoamine Oxidase A/B
Mini-Reviews in Medicinal Chemistry Antisense Treatment in Human Prostate Cancer and Melanoma
Current Cancer Drug Targets The Prevalence of Depression in Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Current Alzheimer Research Development and Optimization by Quality by Design Strategies of Frovatriptan Orally Disintegrating Tablets for Migraine Management
Current Drug Delivery